Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience by Pagnano, Kátia Borgia Barbosa et al.
173
INTRODUCTION
During the 1980’s and 1990’s an increasing
majority of patients with AML achieved CR and the
proportion of patients remaining in permanent remis-
sion also improved.1,2 Intensified induction therapy
may affect the long term survival without an apparent
effect on the initial response rate.3 CR rates in
previously untreated patients with de novo AML using
High Dose Ara-C (HDAC) have been reported to be
50-80%.4,5
The general trend in the therapeutic strategy has
invariably been aimed towards more aggressive
treatment administered as soon as CR is achieved. The
reason for this has been to provide a maximum of anti-
tumor effect, a so-called consolidation or intensifica-
tion treatment.6
Three intensive consolidation strategies are
currently proposed for younger adults with AML in first
CR: allogeneic or autologous bone marrow transplan-
tation (BMT) or intensive consolidation chemo-
therapy.7,8 For patients who are younger than 45,
myeloablative treatment with allogeneic BMT, from an
identical HLA sibling donor, has become an accepted
treatment, when a donor is available. However,
allogeneic BMT carries substantial procedural risk
related to mortality and morbidity, resulting in a 5-
year overall survival of around 50%.8 Autologous stem
cell transplantation offers the possibility of performing
the same myeloablative regimen in patients without
a compatible donor and without the risks associated
with graft-versus-host-disease (GVHD).7
Results from randomized studies comparing
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CONTEXT: Young patients affected by acute myeloid leukemia (AML)
achieve complete remission (CR) using conventional chemotherapy
in about 55-85%. However, 30% of patients fail to achieve CR and
the remission duration is often only about 12 months. More intensive
treatment after CR seems to be necessary in order to maintain CR
and obtain a definitive cure. In Brazil, few reports have been
published on this important subject.
OBJECTIVE: The aim of this study was to describe a Brazilian expe-
rience in the treatment of “de novo” acute myeloid leukemia (AML)
in younger adult patients (age < 60 years).
DESIGN: Retrospective analysis.
SETTING: University Hospital, Hematology and Hemotherapy Cen-
ter, State University of Campinas, Brazil.
PARTICIPANTS: Newly diagnosed cases of “de novo” AML in the
period from January 1994 to December 1998 were evaluated ret-
rospectively, in relation to response to treatment, overall survival
(OS) and disease free survival (DFS). Cases with acute promyelocytic
leukemia (APL) were also included in this analysis.
RESULTS: On the basis of an intention to treat, 78 cases of AML,
including 17 cases of APL, were evaluated. The overall median follow-
up was 272 days. The complete remission (CR) rate was 63.6% in
the AML group (excluding APL) and 78% in the APL group. The 5-
year estimated disease-free survival (DFS) was 80% for the APL group
and 34% for the AML group (P = 0.02). The 5-year estimated over-
all survival (OS) was 52% for the APL group and 20.5% for the AML
group, respectively (P = NS). Relapse was observed in 12/39
(30.7%) patients with AML and 1/11 (9%) with APL.
CONCLUSIONS: These results are similar to those reported in the
literature. However, relapse and mortality rates remain high, and a
search for more aggressive strategies in order to prevent relapse is
recommended.
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chemotherapy alone to allogeneic and autologous
bone marrow transplantation have become available.7-
11 Better results are seen in APL, a distinct subtype of
AML, in which a balanced reciprocal translocation
between chromosomes 15 and 17 results in the union
of portions of the promyelocytic leukemia gene with
the gene for retinoic acid receptor alpha. The disease
typically presents with a life-threatening hemorrhagic
diathesis, which worsens by cytotoxic chemotherapy,
with early hemorrhagic deaths of about 10-20%. The
use of all-trans-retinoic acid (ATRA) followed by
anthracycline in the induction therapy of APL has
improved the outcome, with the CR rate reaching more
than 90% and reducing the incidence of relapse.12,13,14
The aim of this study was to describe a Brazilian
experience in the treatment of adult patients affected
by AML, including APL, providing a basis for more
intensive approaches in the future.
METHODS
Patients. Patients under 60 years of age, with
previously untreated “de novo” acute myeloid leukemia
(AML) diagnosed and treated between 1994 and 1998
at the State University of Campinas were enrolled in
this study. The diagnosis was assessed by bone marrow
(BM) aspiration showing at least 30% of blasts, or by a
bone marrow biopsy, in the case of associated
myelofibrosis. Each case was classified according to
the French-American-British (FAB) System.15,16 Patients
with a previous history of myelodysplasia,
myeloproliferative disease and previous chemotherapy
or radiotherapy treatment were not included in this
study.
Leukemia diagnosis. For the classification we used
the procedures recommended by Scott, et al.23 We used
conventional cytochemistry techniques for the
classification of AML: Sudan Black, PAS and unspe-
cific esterase, with and without NaF inhibition. Cases
considered to be Sudan Black negative were studied
by flow cytometry with the following antibodies: CD45,
CD10/CD19, CD3/DR, CD7/CD33, CD14/CD34, CD13 and
myeloperoxidase (MPO). Immunocytochemistry in
slides was performed with antibodies to glycophorin,
CD41 and CD62 when necessary. APL was classified
by morphology. Cytogenetic studies were available for
only two APL patients: one presented t (15.17) and
PCR positive for the translocation PML/RARα. The
other one had variant microgranular morphology and
had a normal karyotype.
Treatment. The induction treatment consisted of
1 or 2 cycles of TAD-9, as described elsewhere.1 Bone
marrow aspiration was performed between the 14th and
21st day after the last day of chemotherapy. Patients
who did not achieve complete remission (CR) after two
cycles of TAD-9 were treated with a salvage regimen,
named MEC.17 Patients who achieved CR were
submitted to two consecutive consolidation cycles,
one with HDAC plus daunorubicin (ARAC 2g/m2 IV
twice a day on days 1-4 and daunorubicin 45 mg/m2
on days 5-7), followed by one cycle of TAD-7, as
described elsewhere.1 After these 2 cycles, patients
were submitted to maintenance treatment for 24
months, with monthly cycles of ARAC 100 mg/m2 SC
twice a day on days 1-5, alternating monthly cyclo-
phosphamide, daunorubicin and thioguanine.2
A search for an HLA identical donor was per-
formed for all patients under 50 years of age, and
allogeneic BMT was proposed to patients with an HLA-
identical sibling donor available (except to APL
patients).
Patients affected by APL received an ATRA-
containing regimen as induction treatment, accord-
ing to initial leukometry. Patients with WBC = 5x109/L
were treated with ATRA. Patients with WBC between
6x109/L and 10x109/L were treated with ATRA and TAD-
9 and patients with WBC >10x109/L at diagnosis
received only conventional chemotherapy as induc-
tion treatment (TAD-9). One patient was treated with
ATRA and daunorubicin as induction. ATRA was
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Table 1. French-American-British classification of 78










not classified* 4 5
Total 78
*3 biphenotypic AML, one case of granulocytic sarcoma.
Table 2. Clinical and laboratory
characteristics of patients with AML
AML group (n=61) APL group(n=17)
median age 32 (14 to 59) 33 (16 to 54) S e x
(M/F) 31/30 7/10
Hb (g/dl) 8.3 (4.5 to 15) 8.0 (5 to 12)
WBC x109 /L 20 (0.4 to 214) 3.3 (0.7 to 49)
% blasts peripheral blood 60.5 (0 to 98) 15 (3 to 91) %
blasts bone marrow 76 (30 to 99) 75.5 (38 to 99)
Platelets x109 /L 42 (2 to 247) 18 (2 to 146)
median follow-up (days) 261.5 (1 to 1842) 419 (4 to 1580)
AML - acute myeloid leukemia; APL - acute promyelocytic leukemia; M -
male; F - female.
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interrupted and chemotherapy added if patients pre-
sented ATRA syndrome and/or leukocytosis. The post
remission therapy for APL patients was the same used
for the other AML subtypes. No allogeneic BMT was
performed in APL patients during the first CR.
Response criteria. CR was defined as more than
1.0x109/L granulocytes and more than 100x109/L plate-
lets in peripheral blood, and normocellular BM
containing less than 5% of blasts cells. Patients who
did not fulfill the above criteria were considered non-
responders.
Statistical methods. Analysis was based on status
of the patients on April 20th 1999, based on the last
follow-up. Overall survival (OS) was defined from the
date of diagnosis and beginning of chemotherapy until
death or last follow-up. Disease free survival (DFS) was
calculated from the date of first complete remission
until the date of death, first relapse or last follow-up
in continuous CR. Survival curves were calculated by
the Kaplan-Meier method and differences between the
curves were analyzed with the log-rank test.18 The pa-
tients were divided into the AML group (n=61) and
APL group (n=17). The comparison between WBC
number on diagnosis was based on descriptive analy-
sis using the Mann-Whitney test.
RESULTS
Between January 1994 and December 1998, 87
patients with age below 60 years old were diagnosed
as AML in our hospital. However, nine patients were
not evaluated because of early death before starting
chemotherapy. Among the 78 evaluated patients, 61
(78.2%) patients were classified as AML group (non-
APL) and 17 (21.8%) were classified as APL. In the AML
group, 31 patients were males and 30 females and the
median age was 32 years (14-59). In the APL group, 7
patients were males and 10 females, with a median
age of 33 years (16-54). The median number of white
blood cells (WBC) at diagnosis was 20 x 109/L (0.4-
214) for the AML group and 3.3 x 109/L (0.7-49) for the
APL group (P = 0.004) (Table 1). The clinical and
laboratory characteristics are shown in Table 1. The
most common FAB subtypes were M4, M2 and M3
(32%, 21.8% and 21.8%, respectively) (Table 2). During
the analysis period, no cases of M7 subtypes were
diagnosed. The overall median follow-up was 254 days
(1-1842) and 540 days (4-1580) for the AML and APL
groups, respectively.
Response. At the end of our observation, 33/78
patients (42.3%) were alive; 32 (41%) in CR and 1 (1.2%)
with refractory disease after relapse; 45/78 (57.6%)
patients died. AML group: 30 out of 61 (49%) patients
reached CR with one cycle of TAD-9. Thirteen out of 61
did not achieved CR using one cycle of TAD-9, and 5 of
them (8.1%) achieved CR after the second cycle of TAD-
9. Three patients (4.9%) achieved CR after salvage
chemotherapy with MEC (2 patients) or HDAC (1
patient). One patient (1.6%) received as an induction
treatment low dose Ara-C due to poor performance
status at diagnosis and achieved CR. A total of 39
patients achieved CR (63.6%). Two patients were
submitted to allogeneic bone marrow transplantation,
while in first CR and remained in CR. Four patients died
during consolidation therapy while in CR. Twelve out of
35 (34.2%) patients relapsed, after a median time of
287.5 days (50-1265) from first CR (AML group). APL
patients: Seven patients with WBC ≤ 5X109/L were treated
initially with ATRA. TAD-9 was associated in 7 cases with
a rise in WBC and/or ATRA syndrome. Eleven out of 14
(78%) patients who used an ATRA-containing regimen
achieved CR. Three patients were treated with
conventional chemotherapy alone and died during
induction. One out of 11 (9%) relapsed, after 22 months
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Figure 1. Overall survival in patients affected by AML.
Figure 2. Disease free survival in patients affected by AML.
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in CR, during maintenance treatment.
Survival. The median survival for alive patients
was 409 days (67-1842) for the AML (non-APL) group
(n=22) and 677 days (118-1580) for the APL group
(n=10). The estimated OS for all patients (AML and
APL groups) was 27% over 5 years. The 5-year esti-
mated OS was 20.5% and 52% for AML and APL groups,
respectively (P = NS). However, the 5-year estimated
DFS was significantly higher in the APL (80%)
compared to the AML group (34%) (P = 0.01). The
overall survival and disease free survival curves for the
two groups of patients are shown in Figures 1 and 2,
respectively.
Causes of death. AML group: 21 out of 61 (34.5%)
patients died during induction treatment. 13 out of 21
(61.9%) died due to infection, 2 out of 21 (9.5%) due to
CNS bleeding, 1 out of 21 (4.8%) due to leukostasis, 1
out of 21 due to acute GVHD, and 4 out of 21 (19%)
due to unknown causes. After consolidation therapy,
4 out of 39 patients (10.2%) died during the aplastic
phase, due to infection; 3 of them after the first cycle
of consolidation (HDAC) and one after the second cycle
of consolidation (TAD-7). Eleven out of 35 patients
(31.4%) died after relapse. One out of 11 (9%) patients
died of bleeding before receiving reinduction treat-
ment. Nine out of 11 (82%) died due to infection, after
reinduction chemotherapy. One out of 11 (9%) was
submitted to allogeneic BMT and died due to progres-
sive disease and central nervous system bleeding.
None of the relapsed patients achieved CR using sal-
vage therapy. No patients died during maintenance
treatment, while in CR. APL group: There were 7 deaths
in this group. Three out of 7 (44%) patients died during
TAD-9 induction, two due to disseminated
intravascular coagulation (DIC) and one due to infec-
tion. Among the patients treated with an ATRA-
containing regimen, 2 out of 7 (28%) patients died due
to ATRA syndrome and one out of 7 (14%) due to
infection. One of the 7 (14%) patients had a late
relapse, 22 months after starting CR and died during
the aplastic phase post-reinduction therapy, due to
infection.
DISCUSSION
In this retrospective study, we analyzed the
results of conventional treatment for patients with
AML, age < 60 years, treated at the University of
Campinas. There are few Brazilian studies published
concerning results of treatment in AML.19 For this age
group, there are many reports referring to CR rates
between 55% to 85%, with prolonged DFS, and cures
in about 25%-30%.4
We used TAD-9 as induction therapy. The CR rate
after the 1st cycle was 49%. The second cycle of TAD-9
brought little improvement to the overall CR (8.1%).
In addition, 4.9% of patients achieved CR with salvage
regimens. The overall CR rate was 63.6%, similar to
those reported in the literature.2,4,5 With standard
induction regimens (3 days of anthracycline and 7 days
of cytarabine), approximately 30% of patients still fail
to achieve CR and the remission duration is often
around 12 months.
HDAC has been successfully used in a number of
combinations in relapsed patients and as post-remis-
sion or consolidation therapy.9,10,11 We used one cycle
of HDAC for consolidation and did not observe high
toxicity and mortality. Thus, this regimen was
demonstrated to be feasible in our patients. Although
many different schedules have been used, including
consolidation with or without prolonged maintenance,
about 25-30% of patients will remain in CR for 5 years.
However, the maintenance of remission is still a chal-
lenge. We observed relapse in 34.7% of the AML group,
half of them occurring during the first year post-remis-
sion. Our maintenance program was not able to sustain
CR in a large number of patients. The 5-year estimated
overall survival for the AML group was 20.5%, similar to
that reported in the literature.2,4,5
Recently, new approaches have been proposed
to intensify AML treatment, with the purpose of de-
creasing relapse incidence, leading to a better OS and
DFS. The first large randomized study comparing
allogeneic BMT, autologous BMT and intensive
consolidation with HDARAC was published by the
EORTC and GIMEMA groups.20 In this study, BMT
resulted in a better DFS than conventional chemo-
therapy. In the GOELAM study, the 3 groups presented
similar results. However, this group used higher doses
of ARAC and idarubicin instead of daunorubicin. In
this study only 32% of patients in CR could be
randomized between autologous BMT and
consolidation with chemotherapy. Moreover, alloge-
neic BMT was performed without previous intensive
consolidation, resulting in a large number of relapses
after bone marrow transplantation. The MRC AML 10
trial study showed a better OS and fewer relapses after
4 cycles of chemotherapy followed by autologous BMT.
However, in this trial HDARAC was not used. Based
on this study, 3 prognostic groups were described
according to cytogenetics, FAB classification and
response to the first cycle of induction.21 The group
with favorable prognosis consisted of patients with
APL or favorable karyotype (inv 16, t(15-17), t(8-21);
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the standard risk group (neither good nor poor) and
the poor risk group were those with adverse karyotype
or > 15% of blasts after the first course of induction.
However, except for APL, there is still no consensus in
the literature for differentiating AML treatment
according to cytogenetic characteristics. In our study,
it was not possible to evaluate cytogenetics in most
of the cases, so we could not stratify the patients into
risk categories according to this criterion.
The treatment of the APL group using chemo-
therapy alone was shown to be inadequate, and high
rates of mortality due to DIC were observed. The use
of all-trans-retinoic acid (ATRA) followed by
anthracycline, in the induction therapy of APL, has
improved the CR rate to greater than 90% and reduced
the incidence of relapse.12,13,14 The addition of ATRA to
chemotherapy during induction of APL has brought a
great improvement in terms of CR and DFS, also in
our patients. DFS was longer in APL (80%) than in the
AML (non-APL) group (34%) (P = 0.02). The difference
in terms of OS between the 2 groups was not
significant, probably due to the small number of APL
patients enrolled. Once CR was achieved, relapse was
a rare event in this group. We did not observe the high
induction mortality rates described by Pulcheri, et al.19
Except for APL, allogeneic bone marrow trans-
plantation from an HLA sibling donor is the treatment
of choice, despite the transplant-related morbidity and
mortality. In our study, patients transplanted in the
first CR had better results than those with refractory
disease. However, few patients have an available
donor. More intensive chemotherapy followed by
autologous BMT, or more intensive consolidation,
should probably reduce the relapse risk and prolong
overall survival.
We may therefore conclude that the overall
results achieved at our Institution represent what is
expected in the literature for conventional chemo-
therapy in AML and APL.
Based on this previous experience, we are in-
troducing a new prospective approach to AML treat-
ment: intensification of consolidation with a second
HDAC, instead of TAD-7, and a randomized study
comparing autologous bone marrow transplantation
versus maintenance treatment, for young patients who
do not have identical sibling HLA donors available.
With this novel strategy, we expect to offer a better
chance of cure for these patients.
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resumo
CONTEXTO: Pacientes adultos com diagnóstico de leucemia mielóide
aguda (LMA) obtém remissão completa (RC) com quimioterapia
convencional em cerca de 55-85% dos casos, e a sua duração é de
aproximadamente 12 meses. Cerca de 30% dos pacientes não
atingem a RC. Para manter a RC e obter cura definitiva parece ser
necessário intensificar o tratamento após a RC. No Brasil, há um
pequeno número de artigos publicados a esse respeito.
OBJETIVO: Descrever a experiência brasileira no tratamento de leu-
cemia mielóide aguda “de novo” em jovens e adultos com idade
inferior a 60 anos.
TIPO DE ESTUDO: Análise retrospectiva.
LOCAL: Hospital das Clínicas e Hemocentro da Universidade Estadual
de Campinas.
PARTICIPANTES: Foram estudados, retrospectivamente, casos novos
de LMA entre 1994 e 1998, com relação à resposta ao tratamento
de quimioterapia, sobrevida global e sobrevivência livre de doença.
RESULTADOS: Entraram no estudo 78 pacientes de LMA, incluindo
17 casos de leucemia promielocítica (LPM). A média de seguimento
foi de 272 dias. A taxa de RC foi de 63,6% nos pacientes com LMA
excluindo-se os pacientes com LPM, e 78% nos pacientes com LPM.
A sobrevida livre de doença em 5 anos foi de 80% nos pacientes
com LPM e 34% para os pacientes com LMA (P=0,01). A sobrevida
global foi de 52% e 20,5% para os pacientes com LPM e LMA
respectivamente (P=NS). Recidiva foi observada em 12/39 (30,7%)
dos pacientes com LMA e 1/11 (9%) na LPM.
CONCLUSÕES: Esses resultados são semelhantes aos encontrados
na literatura, entretanto, o número de recidivas e a mortalidade
mantém-se alta, recomendando-se pesquisa de estratégias mais
agressivas para prevenir recidivas.
PALAVRAS-CHAVE: Leucemia mielóide aguda. Quimioterapia.
Transplante de medula óssea. Sobrevida.
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